SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Meta forced to unmask anonymous Facebook users in defamation lawsuit

Exit dreams and corporate reality: Untold challenges of Israeli tech acquisitions

What went wrong at AnyVision? Lessons from a $352M flameout

2025 is bringing “a search for meaning” among Israelis, inspiring entrepreneurial dreams

Buzz

Most popular

Daily

Weekly

1

Facial recognition firm Oosto, formerly AnyVision, sold for $125M after raising $352M

2

"Wiz is the world's fastest-growing cyber company and together we can build the largest security company to come out of Israel"

3

Warburg Pincus Signs Deal to Acquire Israeli Credit Card Issuer for $680 Million

4

"Everyone will be a manager" - what the world of work will look like with AI agents

5

Survey finds 50% of high-tech startups in Israel may exhaust funds in six months

Gilead

6 stories about Gilead

מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman

The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies

פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy

Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights

ההכרזה של דולנד טראמפ על ירושלים 2

CTech’s Daily Israeli Tech News Roundup

Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich

With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich

The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales